Meracle Health

Core business

Meracle Health brings relief and assurance to patients with respiratory and chronic ailments by optimizing the delivery of therapy in a safe, reliable and efficient manner.

Products & services

Meracle Health developed the Whizz, a simple, intuitive and convenient solution to improve the management of chronic respiratory conditions by increasing the efficiency of medication delivered into the lungs while tracking intake data to augment the management and assessment of treatment outcomes. The Whizz is the only solution in the market that addresses technique and compliance at the same time, solving the challenges faced by 7 in 10 patients, who struggle with ineffective and inconsistent inhaled medication intake. Through trials, we have shown that the Whizz helped patients overcome these hurdles, leading to reduced symptoms and better quality of life.

Major HealthTech projects

The Whizz was designed and developed under a certified ISO13485 Quality Management System and is currently at Technology Readiness Level (TRL) 7, where it has been used and tested in operational environment via usability and feasibility clinical trials. Feedback from parents with asthmatic children has yielded strong support for the Whizz with 7 out of 10 parents willing to replace their current product with the Whizz. Two trials were conducted at National University Hospital (NUH), Singapore. Firstly, a usability trial with parents of children with asthma, where parents brought home the Whizz and tested its features and usability. This trial showed a 100% increase in correct technique and good compliance, 2 crucial metrics of asthma control, with positive validation from patients and their caregivers. Feasibility clinical trials with children aged 7-18 with asthma found marked improvements in asthma control when the Whizz is used for 3 months in the home environment.

Looking for

Chronic respiratory conditions are a huge and growing problem, leading to increasing burden on an already overstretched healthcare system. In Europe, approximately 50 million people are affected by asthma and COPD and we want to explore the most effective method of reaching out these patient population. Our goal in Europe is to engage with partners to drive and support market access. We want to work with clinical key opinion leaders and government agencies to navigate the healthcare policies and landscape as well as the buyer and reimbursement dynamics. We want to connect with go to market implementation partners including insurers, distributors, pharmaceutical companies, as well as telehealth platforms to bundle the Whizz with inhaled medication, thus complementing their current solution offerings and deliver this life saving solution to the hands of patients.